Arbutus Biopharma(ABUS) - 2024 Q3 - Quarterly Results

EXHIBIT 99.1 Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial were generally safe and well-tolerated with evidence of receptor occupancy Now dosing cHBV patients with AB-101 in Part 3 of the Phase 1a/1b clinical trial Cash runway into the fourth quarter of 2 ...